INOGEN, INC. Revenue from Contract with Customer, Excluding Assessed Tax
INOGEN, INC. (INGN) reported Revenue from Contract with Customer, Excluding Assessed Tax of $83.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-07
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $83.53M, a 5.50% increase year-over-year.
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $72.40M, a 5.75% increase year-over-year.
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $68.57M, a 3.42% increase year-over-year.
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $79.09M, a 5.55% increase year-over-year.
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $295.30M, a 5.94% increase from fiscal 2024.
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $278.76M, a 10.79% increase from fiscal 2023.
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $251.61M, a 21.51% decline from fiscal 2022.
- INOGEN, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $320.55M, a 2.83% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $83.53M 10-Q · filed 2026-08-07 | $155.93M 10-Q · filed 2026-08-07 | $224.50M derived: sum of 3 quarters · filed 2026-08-07 | $303.59M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $72.40M 10-Q · filed 2026-05-08 | $140.98M derived: sum of 2 quarters · filed 2026-05-08 | $220.07M derived: sum of 3 quarters · filed 2026-05-08 | $299.24M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $68.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $147.66M derived: sum of 2 quarters · filed 2026-02-27 | $226.83M derived: sum of 3 quarters · filed 2026-08-07 | $295.30M 10-K · filed 2026-02-27 |
| 2025-09-30 | $79.09M 10-Q · filed 2025-11-06 | $158.26M derived: sum of 2 quarters · filed 2026-08-07 | $226.73M 10-Q · filed 2025-11-06 | $293.04M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $79.17M 10-Q · filed 2026-08-07 | $147.64M 10-Q · filed 2026-08-07 | $213.95M derived: sum of 3 quarters · filed 2026-08-07 | $288.88M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $68.47M 10-Q · filed 2026-05-08 | $134.78M derived: sum of 2 quarters · filed 2026-05-08 | $209.71M derived: sum of 3 quarters · filed 2026-05-08 | $284.13M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $66.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $141.24M derived: sum of 2 quarters · filed 2026-02-27 | $215.66M derived: sum of 3 quarters · filed 2026-02-27 | $278.76M 10-K · filed 2026-02-27 |
| 2024-09-30 | $74.93M 10-Q · filed 2025-11-06 | $149.35M derived: sum of 2 quarters · filed 2025-11-06 | $212.45M 10-Q · filed 2025-11-06 | $271.85M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $74.42M 10-Q · filed 2025-08-08 | $137.52M 10-Q · filed 2025-08-08 | $196.92M derived: sum of 3 quarters · filed 2026-02-27 | $264.90M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $63.09M 10-Q · filed 2025-05-08 | $122.50M derived: sum of 2 quarters · filed 2026-02-27 | $190.47M derived: sum of 3 quarters · filed 2026-02-27 | $258.81M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $59.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $127.38M derived: sum of 2 quarters · filed 2026-02-27 | $195.72M derived: sum of 3 quarters · filed 2026-02-27 | $251.61M 10-K · filed 2026-02-27 |
| 2023-09-30 | $67.97M 10-Q · filed 2024-11-08 | $136.32M derived: sum of 2 quarters · filed 2024-11-08 | $192.20M 10-Q · filed 2024-11-08 | $265.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $68.34M 10-Q · filed 2024-08-07 | $124.23M 10-Q · filed 2024-08-07 | $197.41M derived: sum of 3 quarters · filed 2025-02-28 | $288.09M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $55.89M 10-Q · filed 2024-05-08 | $129.07M derived: sum of 2 quarters · filed 2025-02-28 | $219.74M derived: sum of 3 quarters · filed 2025-02-28 | $309.03M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $73.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $163.86M derived: sum of 2 quarters · filed 2025-02-28 | $253.15M derived: sum of 3 quarters · filed 2025-02-28 | $320.55M 10-K · filed 2025-02-28 |
| 2022-09-30 | $90.67M 10-Q · filed 2023-11-09 | $179.96M derived: sum of 2 quarters · filed 2023-11-09 | $247.37M 10-Q · filed 2023-11-09 | $310.74M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-06-30 | $89.29M 10-Q · filed 2023-08-08 | $156.69M 10-Q · filed 2023-08-08 | $220.06M derived: sum of 3 quarters · filed 2024-03-01 | $301.04M derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-03-31 | $67.40M 10-Q · filed 2023-05-05 | $130.77M derived: sum of 2 quarters · filed 2024-03-01 | $211.75M derived: sum of 3 quarters · filed 2024-03-01 | $302.05M derived: sum of 4 quarters · filed 2024-03-01 |
| 2021-12-31 | $63.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $144.34M derived: sum of 2 quarters · filed 2024-03-01 | $234.65M derived: sum of 3 quarters · filed 2024-03-01 | $311.73M 10-K · filed 2024-03-01 |
| 2021-09-30 | $80.97M 10-Q · filed 2022-11-03 | $171.28M derived: sum of 2 quarters · filed 2022-11-03 | $248.36M 10-Q · filed 2022-11-03 | $312.99M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $90.30M 10-Q · filed 2022-08-04 | $167.38M 10-Q · filed 2022-08-04 | $232.01M derived: sum of 3 quarters · filed 2023-02-24 | $298.82M derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $77.08M 10-Q · filed 2022-05-05 | $141.71M derived: sum of 2 quarters · filed 2023-02-24 | $208.52M derived: sum of 3 quarters · filed 2023-02-24 | $274.13M derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $64.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $131.44M derived: sum of 2 quarters · filed 2023-02-24 | $197.05M derived: sum of 3 quarters · filed 2023-02-24 | $280.19M 10-K · filed 2023-02-24 |
| 2020-09-30 | $66.81M 10-Q · filed 2021-11-04 | $132.42M derived: sum of 2 quarters · filed 2021-11-04 | $215.56M 10-Q · filed 2021-11-04 | $289.03M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $65.61M 10-Q · filed 2021-08-04 | $148.75M 10-Q · filed 2021-08-04 | $222.22M derived: sum of 3 quarters · filed 2022-02-24 | $308.62M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $83.14M 10-Q · filed 2021-05-04 | $156.61M derived: sum of 2 quarters · filed 2022-02-24 | $243.00M derived: sum of 3 quarters · filed 2022-02-24 | $338.87M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $73.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $159.87M derived: sum of 2 quarters · filed 2022-02-24 | $255.73M derived: sum of 3 quarters · filed 2022-02-24 | $340.55M 10-K · filed 2022-02-24 |
| 2019-09-30 | $86.39M 10-Q · filed 2020-11-04 | $182.25M derived: sum of 2 quarters · filed 2020-11-04 | $267.07M 10-Q · filed 2020-11-04 | $347.81M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $95.86M 10-Q · filed 2020-08-04 | $180.68M 10-Q · filed 2020-08-04 | $261.41M derived: sum of 3 quarters · filed 2021-02-24 | $351.13M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $84.82M 10-Q · filed 2020-05-05 | $165.55M derived: sum of 2 quarters · filed 2021-02-24 | $255.26M derived: sum of 3 quarters · filed 2021-02-24 | $347.25M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $80.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $170.44M derived: sum of 2 quarters · filed 2021-02-24 | $262.43M derived: sum of 3 quarters · filed 2021-02-24 | $336.01M 10-K · filed 2021-02-24 |
| 2018-09-30 | $89.71M 10-Q · filed 2019-11-05 | $181.70M derived: sum of 2 quarters · filed 2019-11-05 | $255.28M 10-Q · filed 2019-11-05 | $313.63M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $91.99M 10-Q · filed 2019-08-07 | $165.57M 10-Q · filed 2019-08-07 | $223.92M derived: sum of 3 quarters · filed 2020-02-25 | $287.06M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $73.58M 10-Q · filed 2019-05-07 | $131.94M derived: sum of 2 quarters · filed 2020-02-25 | $195.07M derived: sum of 3 quarters · filed 2020-02-25 | $253.11M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $58.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $121.49M derived: sum of 2 quarters · filed 2020-02-25 | $179.53M derived: sum of 3 quarters · filed 2020-02-25 | $225.49M 10-K · filed 2020-02-25 |
| 2017-09-30 | $63.14M 10-Q · filed 2018-11-06 | $121.17M derived: sum of 2 quarters · filed 2018-11-06 | $167.14M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $58.04M 10-Q · filed 2018-08-07 | $104.00M 10-Q · filed 2018-08-07 | ||
| 2016-12-31 | $168.17M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B | |
| NutriBand Inc. (NTRB) | United States | $0.109B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| ALPHA PRO TECH LTD (APT) | $0.052B | 13.63 | |
| MILESTONE SCIENTIFIC INC. (MLSS) | United States | $0.036B | -6.85 |
| Lifeward Ltd. (LFWD) | $0.021B | ||
| ENvue Medical, Inc. (FEED) | United States | $0.011B |